XLO — Xilio Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-10-22.
Performance
Technicals
Others in Healthcare
Measured signals that fired on XLO
| date | signal | measured base rate |
|---|---|---|
| 2026-07-13 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-13 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel Director | Open-market purchase | 5.0K | 8.79 | 44.0K |
| 2026-01-02 | Frankenfield Christopher James Chief Financial Officer | Open-market sale 10b5-1 plan | 7.0K | 0.64 | 4.5K |
| 2026-01-02 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Open-market sale 10b5-1 plan | 1.8K | 0.64 | 1.2K |
| 2026-01-01 | Russo Rene PRESIDENT AND CEO | Option exercise | 44.2K | — | — |
| 2026-01-01 | Frankenfield Christopher James Chief Financial Officer | Option exercise 10b5-1 plan | 19.4K | — | — |
| 2026-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Option exercise | 16.6K | — | — |
| 2026-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Option exercise 10b5-1 plan | 5.0K | — | — |
| 2025-06-17 | Shannon James Samuel Director | Open-market purchase | 25.0K | 0.69 | 17.2K |
| 2025-06-16 | Shannon James Samuel Director | Open-market purchase | 45.0K | 0.69 | 31.1K |
| 2025-06-16 | Russo Rene PRESIDENT AND CEO | Open-market purchase | 36.3K | 0.68 | 24.7K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 5.6M | 664.0K |
| GILEAD SCIENCES, INC. | 5.5M | 650.4K |
| Frazier Life Sciences Management, L.P. | 3.6M | 422.5K |
| Sio Capital Management, LLC | 1.3M | 152.5K |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | 123.7K |
| Caligan Partners LP | 943.0K | 112.1K |
| Merck & Co., Inc. | 891.3K | 106.0K |
| Stonepine Capital Management, LLC | 539.6K | 64.2K |
| MORGAN STANLEY | 483.5K | 57.5K |
| RENAISSANCE TECHNOLOGIES LLC | 416.9K | 49.6K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M · 2026-08-12
- Xilio Therapeutics, Inc. (XLO) filed form 8-K · 2026-08-12 · SEC EDGAR
Ask the AI about XLO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →